IL-6 and MYC collaborate in plasma cell tumor formation in mice

Blood

Volumn 115, Issue 9, 2010, Pages 1746-1754

  Rutsch, Sebastian ^a,e   Neppalli, Vishala T ^b   Shin, Dong Mi ^c   DuBois, Wendy ^d   Morse III, Herbert C ^c   Goldschmidt, Hartmut ^a   Janz, Siegfried ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF IOWA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MYC PROTEIN; PROTEIN BCL XL; STAT3 PROTEIN; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL RESEARCH; CONTROLLED STUDY; GENE INSERTION; LATENT PERIOD; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GENETICS; HUMAN; HYPERPLASIA; IMMUNOLOGY; ONCOGENE MYC; PATHOLOGY; PLASMA CELL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; HYPERPLASIA; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PLASMA CELLS; PLASMACYTOMA; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 77950343306     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237941     Document Type: Article

References (50)

1. Anderson KC, Hannah AL, Pazdur R, Farrell AT. A strategic framework for novel drug development in multiple myeloma. Br J Haematol. 2007;138(2): 153-159. (Pubitemid 46976325)
2. Mitsiades CS, Anderson KC, Carrasco DR. Mouse models of human myeloma. Hematol Oncol Clin North Am. 2007;21(6):1051-1069.
3. Potter M. Neoplastic development in plasma cells. Immunol Rev. 2003;194:177-195.
4. Rosenbaum H, Harris AW, Bath ML, et al. An Eμ-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J. 1990; 9:897-905.
5. Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S. BCL2 accelerates inflammation- induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Res. 2003;63(24):8656- 8663. (Pubitemid 38064040)
6. Takizawa M, Tolarova H, Li Z, et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med. 2008;205(9): 1949-1957.
7. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003; 101(5):1919-1927. (Pubitemid 36237594)
8. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180.
9. Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A. 2002;99(3): 1509-1514. (Pubitemid 34136523)
10. McNeil N, Kim JS, Ried T, Janz S. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. Genes Chromosomes Cancer. 2005;43(2):137-146. (Pubitemid 40570733)
11. Janz S, Müller J, Shaughnessy J, Potter M. Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc Natl Acad Sci U S A. 1993; 90(15):7361-7365. (Pubitemid 23222450)
12. Park SS, Kim JS, Tessarollo L, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005;65(4): 1306-1315. (Pubitemid 40270157)
13. Cheung WC, Kim JS, Linden M, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004;113(12):1763-1773. (Pubitemid 39071668)
14. Zhang S, Qian X, Redman C, et al. p16(INK4a) gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene. 2003;22(15): 2285-2295. (Pubitemid 36566784)
15. Bliskovsky V, Ramsay ES, Scott J, et al. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A. 2003;100(25): 14982-14987. (Pubitemid 37518003)
16. Eμ gene- insertion mice. J Pathol. 2006;209(1):44-55.
17. Park SS, Shaffer AL, Kim JS, et al. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res. 2005;65(17):7644-7652.
18. Kovalchuk AL, Kishimoto T, Janz S. Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. Leukemia. 2000;14(6):1127-1135. (Pubitemid 30389518)
19. Morse HC 3rd, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100(1):246-258.
20. Qi CF, Zhou JX, Lee CH, et al. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res. 2007;67(6):2439-2447.
21. National Center for Biotechnology Information. Gene Expression Omnibus database. Available at: http://www.ncbi.nlm.nih.gov/geo/. Accessed November 2009.
22. Kovalchuk AL, Mushinski EB, Janz S. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia. 2000;14:909-921. (Pubitemid 30235071)
23. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003; 22(56):9007-9021.
24. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia. 2002;16(6):1182-1188. (Pubitemid 34618857)
25. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer. 2007;110(9):1911-1928. (Pubitemid 350036849)
26. Ishikawa H, Tsuyama N, Kawano MM. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Int J Hematol. 2003; 78(2):95-105. (Pubitemid 37021948)
27. Shacter E, Arzadon GK, Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood. 1992;80(1):194-202.
28. Vink A, Coulie P, Warnier G, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med. 1990; 172(3):997-1000.
29. Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol. 1997;151(3):689-696. (Pubitemid 27385600)
30. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995; 182(1):243-248.
31. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85(4):863-872.
32. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol. 2005;23:1-21. (Pubitemid 40563163)
33. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
34. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13): 4653-4665. (Pubitemid 37323267)
35. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
36. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-4323. (Pubitemid 35266292)
37. Rabe B, Chalaris A, May U, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111(3):1021-1028.
38. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007;13(21):6469-6478. (Pubitemid 350075037)
39. Younes H, Leleu X, Hatjiharissi E, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007;13(13): 3771-3775. (Pubitemid 47037580)
40. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005; 11(11):4251-4258. (Pubitemid 40791592)
41. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67(3):871-875. (Pubitemid 46270739)
42. Enomoto A, Rho MC, Komiyama K, Hayashi M. Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells. J Nat Prod. 2004;67(12):2070- 2072. (Pubitemid 40092557)
43. Hausherr A, Tavares R, Schaffer M, et al. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene. 2007;26(34):4987-4998. (Pubitemid 47172652)
44. Park J, Ahn KS, Bae EK, et al. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs. 2008;19(8):777-782.
45. Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009;113(4):846-855.
46. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP- BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res. 2009;315(3):485-497.
47. Garcia-Bates TM, Bernstein SH, Phipps RP. Peroxisome proliferator- activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin Cancer Res. 2008;14(20):6414-6425.
48. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114-122.
49. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14(9):2519-2526.
50. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339-342. (Pubitemid 24104268)